Ruxolitinib cream is a prescription topical medication used in the treatment of immune-mediated skin disorders, particularly non-segmental vitiligo and mild to moderate atopic dermatitis (eczema). It contains Ruxolitinib, a potent Janus Kinase (JAK) inhibitor, which works by targeting specific pathways involved in inflammation and abnormal immune responses in the skin. The cream acts by inhibiting JAK1 and JAK2 enzymes that play a key role in cytokine signaling. By blocking these pathways, Ruxolitinib helps reduce inflammation, itching, redness, and immune-driven skin damage. In patients with vitiligo, it supports the repigmentation process by controlling immune activity that destroys melanocytes, while in atopic dermatitis it helps calm irritated skin and restore the skin barrier. Ruxolitinib cream is applied topically to affected areas, usually twice daily or as directed by a healthcare professional. It is intended for external use only and should be applied to clean, dry skin. The cream is generally non-greasy and absorbs well, making it suitable for regular dermatological use. Consistent application as prescribed is important to achieve optimal therapeutic results. Most patients tolerate Ruxolitinib cream well. Common side effects may include mild application-site reactions such as redness, burning sensation, acne, or itching. These effects are usually temporary and resolve with continued use. Serious side effects are rare when used topically but patients should follow medical advice closely, especially when applying over large skin areas or for prolonged periods. Ruxolitinib cream should not be used in patients with active skin infections unless treated appropriately. It is also advised to consult a doctor before use in children, pregnant or breastfeeding women, or individuals with weakened immune systems. Ruxolitinib cream represents an advanced, targeted approach in dermatology, offering effective symptom control and visible skin improvement when used under medical supervision. It provides a valuable treatment option for patients seeking modern, non-steroidal therapy for chronic inflammatory skin conditions.